.png "T2 Biosystems (NASDAQ: TTOO)")
JonesTrading analyst Soumit Roy reiterated a Buy rating on T2 Biosystems (TTOO) today and set a price target of $2.50. The company’s shares closed last Monday at $0.72, close to its 52-week low of $0.52.
According to TipRanks.com, Roy is a 5-star analyst with an average return of 19.3% and a 38.9% success rate. Roy covers the Healthcare sector, focusing on stocks such as Monopar Therapeutics Inc, Aeglea Biotherapeutics, and Mirati Therapeutics.
Currently, the analyst consensus on T2 Biosystems is a Moderate Buy with an average price target of $2.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $5.38 and a one-year low of $0.52. Currently, T2 Biosystems has an average volume of 706.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
T2 Biosystems, Inc. engages in the development of proprietary technology platform. It offers the T2 Magnetic Resonance technology which enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types. It products include T2Bacteria Panel, T2Candida Panel, T2Dx Instrument, AND T2MR Technology.
